Applied Therapeutics to Present at the 2024 UBS Global Healthcare Conference

APLT 11.05.2024

SERA-AI Powered Highlights
Date of Upcoming Event:2024-11-12
Name of Upcoming Event:2024 UBS Global Healthcare Conference
Full Press ReleaseSEC FilingsOur APLT Tweets

About Gravity Analytica

Recent News

  • 01.21.2025 - Applied Therapeutics Appoints Reena Thomas Colacot as Vice President and Head of Quality
  • 12.20.2024 - Applied Therapeutics Appoints John H. Johnson as Executive Chairman
  • 11.27.2024 - Applied Therapeutics Receives Complete Response Letter from U.S. FDA Regarding New Drug Application for Govorestat for Classic Galactosemia

Recent Filings

  • 12.20.2024 - 4 Statement of changes in beneficial ownership of securities
  • 12.20.2024 - 3 Initial statement of beneficial ownership of securities
  • 12.20.2024 - 8-K Current report
PDF Version

NEW YORK, Nov. 05, 2024 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, today announced that it will present at the 2024 UBS Global Healthcare Conference on Tuesday, November 12, 2024, at 7:15 a.m. PT in Rancho Palos Verdes, California.

A live webcast for this event will be accessible on the Events page under the Investor Relations section of the Applied Therapeutics website atwww.appliedtherapeutics.com. A replay of the webcast will be archived on the Company’s website for 90 days following the event.

About Applied Therapeutics

Applied Therapeutics is a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need. The Company’s lead drug candidate, govorestat, is a novel central nervous system penetrant Aldose Reductase Inhibitor (ARI) for the treatment of CNS rare metabolic diseases, including Galactosemia, SORD Deficiency, and PMM2-CDG. The Company is also developing AT-001, a novel potent ARI, for the treatment of Diabetic Cardiomyopathy, or DbCM, a fatal fibrosis of the heart. The preclinical pipeline also includes AT-003, an ARI designed to cross through the back of the eye when dosed orally, for the treatment of Diabetic retinopathy.

To learn more, please visitwww.appliedtherapeutics.comand follow the company on Twitter @Applied_Tx.

Contacts

Investors:Julie Seidel/Andrew Vulis646-970-0543appliedtherapeutics@argotpartners.com

Media:media@appliedtherapeutics.com

Please be aware that the following content has been generated by an AI system and may contain errors, inconsistencies, or outdated information. It is provided as-is without any warranties or guarantees of accuracy. We strongly recommend using this content as a starting point for further research and consultation with relevant experts or authorities. We disclaim any liability for damages or losses resulting from the use or reliance on this content.Please note that this is a beta version of the Gravity Analytica LLC’s AI Service which isstill undergoing final testing before its official release. Theplatform, its software and all content found on it are provided on an“as is” and “as available” basis. Gravity Analytica LLC does not give any warranties,whether express or implied, as to the suitability or usability of thisservice, webpage, or its software or any of its content.Should you encounter any bugs, glitches, lack of functionality orother problems on the website, please let us know immediately so wecan rectify these accordingly. Your help in this regard is greatlyappreciated! You can write to us at this addressteam@gravityanalytica.com